 |
20 Diseases |  |
6 Trials |
|
6 Trials |  |
84 News |  |
| 12» |
- || OvaRex (oregovomab) / CanariaBio
P2 data, Journal: OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer. (Pubmed Central) - Jun 28, 2024
P2
Herein, we described the rationale and design of OPERA/KGOG 3065/APGOT-OV6, a multicenter, investigator-initiated, two-cohort, single-arm phase II trial, aimed at examining the efficacy of oregovomab plus non-platinum-based chemotherapy in patients with PARPi/platinum-resistant ovarian cancer. The primary end point was the objective response rate, according to RECIST 1.1.Clinical Trial Registration: NCT05407584 (ClinicalTrials.gov).
- | OvaRex (oregovomab) / CanariaBio
Biomarker, Preclinical, Journal, PARP Biomarker, PARP Companion diagnostic: The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers. (Pubmed Central) - Jun 8, 2024
P=N/A
This clinical study aims at generating PDX and ex vivo models (PDTO, ADS, and explants) from tumors or ascites of ovarian cancer patients who will undergo surgical procedure or paracentesis. We aim at demonstrating the predictive value of ex vivo models for their potential use in routine clinical practice as part of precision medicine, as well as establishing a collection of relevant ovarian cancer models that will be useful for the evaluation of future innovative therapies.
- OvaRex (oregovomab) / CanariaBio, Zejula (niraparib) / GSK, J&J
Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer: FLORA-4 study. (Hall A; Poster Bd #: 457) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1899;
P3
Combination oregovomab and niraparib in patients with platinum sensitive EOC was well tolerated with no new safety signals. Translational research is ongoing to assess biomarkers of early humoral response.
- || OvaRex (oregovomab) / CanariaBio
Trial primary completion date, Combination therapy: Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Oct 17, 2023
P1b/2, N=54, Recruiting, Sponsor: CanariaBio Inc.
Translational research is ongoing to assess biomarkers of early humoral response. Trial primary completion date: Apr 2023 --> Apr 2024
- OvaRex (oregovomab) / CanariaBio
Trial completion date, Trial primary completion date: QPT-ORE-004: A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. (clinicaltrials.gov) - Aug 30, 2023
P2, N=10, Active, not recruiting, Sponsor: CanariaBio Inc.
Trial primary completion date: Apr 2023 --> Apr 2024 Trial completion date: May 2024 --> Oct 2024 | Trial primary completion date: Sep 2023 --> Jan 2024
- OvaRex (oregovomab) / CanariaBio
Enrollment closed, Trial completion date, Trial primary completion date: QPT-ORE-004: A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. (clinicaltrials.gov) - Jul 5, 2023
P2, N=10, Active, not recruiting, Sponsor: CanariaBio Inc.
Trial completion date: May 2024 --> Oct 2024 | Trial primary completion date: Sep 2023 --> Jan 2024 Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2023 --> Sep 2023
- ||||| OvaRex (oregovomab) / CanariaBio
Enrollment closed, Trial primary completion date, Surgery, Metastases: FLORA-5: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (clinicaltrials.gov) - Jun 26, 2023
P3, N=615, Active, not recruiting, Sponsor: CanariaBio Inc.
Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2023 --> Sep 2023 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2024 --> Sep 2025
- OvaRex (oregovomab) / CanariaBio
FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC) (On Demand | Hall A; Poster Bd # 313b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2265;
P3
518 of the planned 602 patients were enrolled at the time of submission. Clinical trial information: NCT04498117.
- OvaRex (oregovomab) / CanariaBio
Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6). (On Demand | Hall A; Poster Bd # 311b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2261;
P2
The trial includes patients with recurrent EOC who have experienced disease progression despite treatment with PARPis and who have either received bevacizumab or are not eligible for bevacizumab treatment...Patients who have received one to three prior lines of chemotherapy are to be assigned to Cohort 1 (oregovamab 2 mg [C1,2,3,5,7 for five doses] + pegylated liposomal doxorubicin [PLD] 40 mg/m2 q4w, n = 28), while patients who have received more than three prior lines of chemotherapy are to be assigned to Cohort 2 (oregovamab 2 mg [C1,2,3,5,7 for five doses] + weekly paclitaxel 80 mg/m2 [D1,8,15 q4w], n = 28)...The study is registered with Clinicaltrials.gov (NCT05407584). Clinical trial information: NCT05407584.
- ||| OvaRex (oregovomab) / CanariaBio
Enrollment open, Metastases: Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer (clinicaltrials.gov) - Mar 31, 2023
P2, N=88, Recruiting, Sponsor: CanariaBio Inc.
Clinical trial information: NCT05407584. Not yet recruiting --> Recruiting
- | OvaRex (oregovomab) / CanariaBio
Journal: Oregovomab Plus Chemo in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5/GOG-3035). (Pubmed Central) - Nov 20, 2022
Not yet recruiting --> Recruiting No abstract available
- |||| OvaRex (oregovomab) / CanariaBio
New P2 trial, Metastases: Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer (clinicaltrials.gov) - Nov 4, 2022
P2, N=88, Not yet recruiting, Sponsor: CanariaBio Inc.
- || OvaRex (oregovomab) / CanariaBio
Trial primary completion date, Combination therapy: Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Oct 24, 2022
P1b/2, N=54, Recruiting, Sponsor: CanariaBio Inc.
No abstract available Trial primary completion date: Dec 2021 --> Apr 2023
- | OvaRex (oregovomab) / CanariaBio
Enrollment change: OPERA: Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment (clinicaltrials.gov) - Sep 30, 2022
P2, N=56, Recruiting, Sponsor: Yonsei University
Trial primary completion date: Dec 2021 --> Apr 2023 N=28 --> 56
- OvaRex (oregovomab) / CanariaBio
OREGOVOMAB AND NON-PLATINUM SINGLE AGENT CHEMOTHERAPY IN PARP INHIBITORRESISTANT OVARIAN CANCER PATIENTS NOT CANDIDATE FOR PLATINUM RETREATMENT: A MULTI-COHORT PHASE II STUDY (KGOG 3065/ APGOT-OV6) () - Sep 9, 2022 - Abstract #IGCS2022IGCS_1067;
Patients were assigned to one of the followings: Cohort 1 (prior 1-3 lines of therapy), PLD (40 mg/m2 q4w till PD) + Oregovomab 2 mg (C1,2,3,5,7 for 5 doses) or Cohort 2 (>3 prior lines of therapy), weekly paclitaxel (80 mg/m2 D1,8,15 q4w till PD) + Oregovomab 2 mg (C1,2,3,5,7 for 5 doses). Trial in progress: there are no available results at the time of submission.
- OvaRex (oregovomab) / CanariaBio
FLORA-5/GOG3035: CHEMO-IMMUNOTHERAPY (PACLITAXEL AND CARBOPLATIN +/OREGOVOMAB) AS FRONT-LINE TREATMENT FOR PATIENTS WITH OVARIAN CANCER. A PHASE III DOUBLE BLIND PLACEBO CONTROLLED, GLOBAL MULTICENTER STUDY. () - Sep 9, 2022 - Abstract #IGCS2022IGCS_1056;
Trial in progress: there are no available results at the time of submission. Trial in progress: there are no available conclusions at time of submission.
- | OvaRex (oregovomab) / CanariaBio
New P2 trial: OPERA: Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment (clinicaltrials.gov) - Jun 7, 2022
P2, N=28, Recruiting, Sponsor: Yonsei University
- OvaRex (oregovomab) / CanariaBio
Enrollment open: QPT-ORE-004: A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. (clinicaltrials.gov) - May 12, 2022
P2, N=10, Recruiting, Sponsor: OncoQuest Pharmaceuticals Inc.
Trial in progress: there are no available conclusions at time of submission. Not yet recruiting --> Recruiting
- OvaRex (oregovomab) / Quest PharmaTech
FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double-blind, placebo-controlled, global, multinational study. (Available On Demand; 486a) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5447;
P3
The study is actively enrolling in the US, Canada, Belgium, Italy, Spain, Czech Republic, Hungary, Poland, Korea, Taiwan, Mexico, Argentina, and Chile. 179 patients were enrolled at time of submission.
- OvaRex (oregovomab) / CanariaBio
New P2 trial: QPT-ORE-004: A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. (clinicaltrials.gov) - Apr 20, 2022
P2, N=10, Not yet recruiting, Sponsor: OncoQuest Pharmaceuticals Inc.
- OvaRex (oregovomab) / Quest PharmaTech
FLORA-5: A phase III double blind placebo controlled multicenter clinical study of front-line chemo-immunotherapy (paclitaxel and carboplatin +/- oregovomab) in patients with advanced epithelial ovarian cancer (GOG-3035) (TBD) - Jan 26, 2022 - Abstract #SGO2022SGO_84;
- OvaRex (oregovomab) / Quest PharmaTech
Phase III double-blind placebo-controlled chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with newly diagnosed, advanced epithelial ovarian cancer (EOC): FLORA-5 Study (Room C [VIRTUAL]) - Nov 30, 2021 - Abstract #ASGO2021ASGO_135;
- || Opdivo (nivolumab) / BMS, OvaRex (oregovomab) / CanariaBio
Enrollment open: ORION-02: Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (clinicaltrials.gov) - Jul 1, 2021
P1/2, N=31, Recruiting, Sponsor: National Cancer Centre, Singapore
179 patients were enrolled at time of submission. Active, not recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Hiltonol (poly-ICLC) / Oncovir, OvaRex (oregovomab) / Quest PharmaTech
[VIRTUAL] Final survival follow-up and translational associations using interval indirect immunization with oregovomab (O) and poly ICLC in patients (pts) with recurrent platinum-resistant ovarian cancer (PROC). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4586;
P1, P3
Immune responsiveness was similar to that observed in a prior study of same day schedule of carboplatin-paclitaxel front-line immunotherapy (Braly, JIT 2009; Battaglia, Cll, 2020) . Patterns of immune response to O in the setting of recurrent ovarian cancer are influenced by concomitant anti-neoplastic therapy .
- OvaRex (oregovomab) / Quest PharmaTech
[VIRTUAL] FLORA-5: Front-line chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab [PCO] versus chemotherapy (Paclitaxel-Carboplatin-Placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III double-blind placebo controlled multinational study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2220;
P3
The study is actively enrolling in the US with 9 patients enrolled at time of submission . Centers in Europe, South America and Asia are expected to begin accruing shortly.
- | OvaRex (oregovomab) / Quest PharmaTech
Journal: Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. (Pubmed Central) - Feb 18, 2021
Since oral treatments as PARP-inhibitors have recently been approved in the OC first-line setting, the possible role of oregovomab needs still to be defined, also considering the intravenous route of administration. The easy to manage toxicity profile makes oregovomab an ideal candidate for association strategies.
- OvaRex (oregovomab) / Quest PharmaTech
[VIRTUAL] FLORA-5: An international phase III double blind placebo-controlled study of front-line chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced ovarian cancer () - Jan 29, 2021 - Abstract #SGO2021SGO_731;
- OvaRex (oregovomab) / Quest PharmaTech
[VIRTUAL] FLORA-5: An international phase III double blind placebo-controlled study of front-line chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced ovarian () - Jan 29, 2021 - Abstract #SGO2021SGO_686;
- ||| OvaRex (oregovomab) / CanariaBio
Trial completion date, Trial termination, Trial primary completion date, Metastases: QPT-ORE-003H: The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer (clinicaltrials.gov) - Dec 21, 2020
P1, N=10, Terminated, Sponsor: OncoQuest Pharmaceuticals Inc.
The easy to manage toxicity profile makes oregovomab an ideal candidate for association strategies. Trial completion date: Sep 2021 --> Nov 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2021 --> Nov 2020; Sponsor Decision to discontinue long-term follow-up
- | Opdivo (nivolumab) / BMS, OvaRex (oregovomab) / CanariaBio
Enrollment change, Trial completion date, Trial termination: ORION-01: Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (clinicaltrials.gov) - Nov 12, 2020
P1/2, N=13, Terminated, Sponsor: National Cancer Centre, Singapore
Trial completion date: Sep 2021 --> Nov 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2021 --> Nov 2020; Sponsor Decision to discontinue long-term follow-up N=32 --> 13 | Trial completion date: Dec 2019 --> Apr 2020 | Recruiting --> Terminated; The study had poor efficacy.
- || Opdivo (nivolumab) / BMS, OvaRex (oregovomab) / CanariaBio
New P1/2 trial: ORION-02: Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (clinicaltrials.gov) - Nov 9, 2020
P1/2, N=31, Active, not recruiting, Sponsor: National Cancer Centre, Singapore
- |||||| OvaRex (oregovomab) / CanariaBio
Enrollment open, Surgery, Metastases: FLORA-5: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (clinicaltrials.gov) - Aug 27, 2020
P3, N=602, Recruiting, Sponsor: OncoQuest Pharmaceuticals Inc.
N=32 --> 13 | Trial completion date: Dec 2019 --> Apr 2020 | Recruiting --> Terminated; The study had poor efficacy. Not yet recruiting --> Recruiting
- |||||||||| OvaRex (oregovomab) / CanariaBio
New P3 trial, Surgery, Metastases: FLORA-5: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (clinicaltrials.gov) - Aug 6, 2020
P3, N=602, Not yet recruiting, Sponsor: OncoQuest Pharmaceuticals Inc.
- || carboplatin / Generic mfg., paclitaxel / Generic mfg., OvaRex (oregovomab) / Quest PharmaTech
Clinical, P2 data, Journal: Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study. (Pubmed Central) - Jul 3, 2020
The previously identified potential clinical benefit of IV CP when administered with oregovomab was further refined in this randomized phase II study. Increases of PFS and OS of statistically and clinically significant magnitude were evident in this study of a front line chemo-immunotherapy treatment of ovarian cancer.
- || carboplatin / Generic mfg., paclitaxel / Generic mfg., OvaRex (oregovomab) / Quest PharmaTech
Clinical, P2 data, Journal, Combination therapy: Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients. (Pubmed Central) - Apr 10, 2020
The study included an Italian cohort in which we demonstrated that adding oregovomab to SOC resulted in increased patient numbers with amplified CA125-specific CD8T lymphocytes/ml peripheral blood counts, which might explain the improved therapeutic effect of SOC + oregovomab over SOC alone. Predictive for oregovomab efficacy was a less suppressive immune environment at baseline as indicated by low numbers of circulating myeloid-derived suppressor cells, subset type 4, and a low neutrophil-and-monocyte to lymphocyte ratio.
- || fluorouracil topical / Generic mfg., OvaRex (oregovomab) / Quest PharmaTech
Clinical, P1/2 data, Journal: Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. (Pubmed Central) - Mar 25, 2020
P2
A combined pancreatic cancer multimodality approach using CIT and radiosensitized radiotherapy is feasible and safe; delivery of immunotherapy can lead to T-cell immunity. Re-evaluation with modern systemic paradigms is recommended.
- | Viracept (nelfinavir) / ViiV Healthcare, Roche, OvaRex (oregovomab) / CanariaBio
Trial completion, Trial completion date, Metastases: Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Nov 15, 2019
P2, N=11, Completed, Sponsor: University of Nebraska
Re-evaluation with modern systemic paradigms is recommended. Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Dec 2018
- Hiltonol (poly-ICLC) / Oncovir, OvaRex (oregovomab) / Quest PharmaTech
A PHASE IB STUDY OF INDIRECT IMMUNIZATION WITH OREGOVOMAB AND TLR3 STIMULATION WITH HILTONOL® (H) IN PATIENTS WITH RECURRENT PLATINUM RESISTANT OVARIAN CANCER (PROC) (E-Poster Area (Americas)) - Sep 10, 2019 - Abstract #IGCS2019IGCS_416;
Safety, compatibility of combining O with H, and early humoral responsiveness to indirect immunization by week-6 have been established. The potential to enhance activity of chemotherapy using O indirect immunization is proposed.
- | Avastin (bevacizumab) / Roche
Retrospective data, Journal: Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis. (Pubmed Central) - Jun 14, 2019
Our study showed a survival advantage conferred by pazopanib and bevacizumab as maintenance therapy in newly diagnosed epithelial ovarian cancer. Further clinical trials are essential to both determine the effect of bevacizumab in the maintenance stage and identify the specific subgroup(s) that benefit.
- | OvaRex (oregovomab) / CanariaBio
Enrollment closed, Metastases: QPT-ORE-003H: The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer (clinicaltrials.gov) - May 22, 2019
P1, N=10, Active, not recruiting, Sponsor: OncoQuest Inc.
Further clinical trials are essential to both determine the effect of bevacizumab in the maintenance stage and identify the specific subgroup(s) that benefit. Recruiting --> Active, not recruiting
- | OvaRex (oregovomab) / CanariaBio
Trial completion, Trial completion date, Metastases: A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer (clinicaltrials.gov) - Oct 16, 2018
P2, N=97, Completed, Sponsor: Quest PharmaTech Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Oct 2018
- | OvaRex (oregovomab) / CanariaBio
Trial primary completion date, Metastases: QPT-ORE-003H: The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer (clinicaltrials.gov) - Oct 11, 2018
P1, N=10, Recruiting, Sponsor: OncoQuest Inc.
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Oct 2018 Trial primary completion date: Aug 2018 --> Sep 2021
- | Viracept (nelfinavir) / ViiV Healthcare, Roche, OvaRex (oregovomab) / CanariaBio
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Apr 26, 2018
P2, N=12, Active, not recruiting, Sponsor: University of Nebraska
Trial primary completion date: Aug 2018 --> Sep 2021 Recruiting --> Active, not recruiting | N=66 --> 12 | Trial primary completion date: Dec 2018 --> Dec 2019
- || OvaRex (oregovomab) / CanariaBio
Trial completion date, Trial primary completion date, Metastases: A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer (clinicaltrials.gov) - Apr 17, 2018
P2, N=97, Active, not recruiting, Sponsor: Quest PharmaTech Inc.
Recruiting --> Active, not recruiting | N=66 --> 12 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2018
- || OvaRex (oregovomab) / CanariaBio
Trial primary completion date, Metastases: A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer (clinicaltrials.gov) - Sep 20, 2017
P2, N=97, Active, not recruiting, Sponsor: Quest PharmaTech Inc.
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Jun 2014 --> Dec 2017
- | OvaRex (oregovomab) / CanariaBio
Enrollment open, Metastases: QPT-ORE-003H: The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer (clinicaltrials.gov) - Jun 20, 2017
P1, N=10, Recruiting, Sponsor: OncoQuest Inc.
Trial primary completion date: Jun 2014 --> Dec 2017 Not yet recruiting --> Recruiting
- | OvaRex (oregovomab) / CanariaBio
New P1 trial, Metastases: QPT-ORE-003H: The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer (clinicaltrials.gov) - May 22, 2017
P1, N=10, Not yet recruiting, Sponsor: OncoQuest Inc.
- | Opdivo (nivolumab) / BMS, OvaRex (oregovomab) / CanariaBio
New P1/2 trial: ORION-01: Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (clinicaltrials.gov) - Apr 4, 2017
P1/2, N=32, Recruiting, Sponsor: National Cancer Centre, Singapore
- ||| OvaRex (oregovomab) / CanariaBio
Enrollment change, Metastases: A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer (clinicaltrials.gov) - Sep 30, 2016
P2, N=97, Active, not recruiting, Sponsor: Quest PharmaTech Inc.
Not yet recruiting --> Recruiting N=80 --> 97
- ||| OvaRex (oregovomab) / CanariaBio
Enrollment closed, Trial primary completion date, Metastases: A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer (clinicaltrials.gov) - Oct 22, 2014
P2, N=80, Active, not recruiting, Sponsor: Quest PharmaTech Inc.
N=80 --> 97 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Jun 2014